

## Appendix 8

### Total reference list to Appendixes

1. Helsedirektoratet. Prioriteringer i helsesektoren. Verdigrunnlag, status og utfordringer Helsedirektoratet ved helsedirektør Bjørn-Inge Larsen; 03-2012 [Available from: <https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/80/Prioriteringer-i-helsesektoren-verdigrunnlag-stauts-og-utfordringer-IS-1967.pdf>].
2. Helsedirektoratet. Veileder for utvikling av kunnskapsbaserte retningslinjer: Helsedirektoratet; 2012 [Available from: <https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/184/Veileder-for-utvikling-av-kunnskapsbaserte-retningslinjer-IS-1870.pdf>].
3. van Driel ML, De Sutter AI, Christiaens TC, De Maeseneer JM. Quality of care: the need for medical, contextual and policy evidence in primary care. *J Eval Clin Pract*. 2005;11(5):417-29.
4. Lavis JN, Davies HTO, Gruen RL, Walshe K, Farquhar CM. Working Within and Beyond the Cochrane Collaboration to Make Systematic Reviews More Useful to Healthcare Managers and Policy Makers. *Healthcare Policy*. 2006;1(2):21-33.
5. Mulrow CD. Systematic Reviews: Rationale for systematic reviews. *BMJ*. 1994;309(6954):597-9.
6. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *BMJ*. 1996;312(7023):71-2.
7. Wiffen P, Eriksson T, Lu H. CHAPTER 3: Asking and formulating the right questions and finding useful resources in evidence-based pharmacy—2nd edition. *European Journal of Hospital Pharmacy: Science and Practice*. 2014;21(1):2-6.
8. Eriksson T, Lu H, Wiffen P. Chapter 6: How to best practice evidence-based pharmacy with your available resources? *European Journal of Hospital Pharmacy*. 2014;21(4):194-201.
9. Wiffen P, Eriksson T, Lu H. CHAPTER 2 introduction to evidence-based practice in evidence-based pharmacy 2nd edition. *European Journal of Hospital Pharmacy: Science and Practice*. 2013;20(6):324-7.
10. WHO. The World Medicines Situation 2011 Geneva: World Health Organization; 2011 [3:[Available from: <http://apps.who.int/medicinedocs/documents/s20054en/s20054en.pdf?ua=1>].
11. Tarn DM, Heritage J, Paterniti DA, Hays RD, Kravitz RL, Wenger NS. Physician communication when prescribing new medications. *Arch Intern Med*. 2006;166(17):1855-62.
12. Horne R, Weinman J, Barber N, Elliott R, Morgan M, Cribb A, et al. Concordance, Adherence and Compliance in Medicine Taking 2005.
13. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keenanasseril A, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2014(11):Cd000011.
14. WHO. Adherence to Long-term Therapies: Evidence for Action: World Health Organization; 2003 [Available from: <http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf>].
15. Cipolle RJ. Pharmaceutical care practice : the patient-centered approach to medication management services. 3rd ed. ed. New York, N.Y: McGraw-Hill; 2012.
16. Hugtenburg JG, Timmers L, Elders PJM, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. *Patient preference and adherence*. 2013;7:675-82.
17. Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. *Int J Nurs Stud*. 2007;44(8):1468-77.
18. Jimmy B, Jose J. Patient Medication Adherence: Measures in Daily Practice. *Oman Med J*. 2011;26(3):155-9.
19. Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. Intentional and unintentional nonadherence to antihypertensive medication. *Ann Pharmacother*. 2005;39(7-8):1198-203.

20. Lindquist LA, Go L, Fleisher J, Jain N, Friesema E, Baker DW. Relationship of health literacy to intentional and unintentional non-adherence of hospital discharge medications. *J Gen Intern Med.* 2012;27(2):173-8.
21. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework. *J Psychosom Res.* 2008;64(1):41-6.
22. Wroe AL. Intentional and unintentional nonadherence: a study of decision making. *J Behav Med.* 2002;25(4):355-72.
23. Iihara N, Nishio T, Okura M, Anzai H, Kagawa M, Houchi H, et al. Comparing patient dissatisfaction and rational judgment in intentional medication non-adherence versus unintentional non-adherence. *J Clin Pharm Ther.* 2014;39(1):45-52.
24. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? *BMC Health Serv Res.* 2012;12:98.
25. Horne R. Compliance, adherence and concordance. In: Taylor KMG, editor. *Pharm Pract (Granada)*. London: Boca Raton : CRC Press; 2001. p. 152-61.
26. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. *Clin Ther.* 1999;21(6):1074-90; discussion 3.
27. Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. *Psychiatr Serv.* 2007;58(9):1187-92.
28. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. *Ann Pharmacother.* 2004;38(2):303-12.
29. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? *Clin Pharmacol Ther.* 1989;46(2):163-8.
30. Lam WY, Fresco P. Medication Adherence Measures: An Overview. *Biomed Res Int.* 2015;2015.
31. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. *Clin Ther.* 2001;23(8):1296-310.
32. Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. *Lancet.* 2005;366(9502):2005-11.
33. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. *JAMA.* 2007;297(2):177-86.
34. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. *BMJ.* 2006;333(7557):15.
35. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. *Health Aff (Millwood).* 2011;30(1):91-9.
36. Dragomir A, Cote R, Roy L, Blais L, Lalonde L, Berard A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. *Med Care.* 2010;48(5):418-25.
37. Weeks G, George J, Maclure K, Stewart D. Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care. *Cochrane Database Syst Rev.* 2016;11:CD011227.
38. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. *Am J Hosp Pharm.* 1990;47(3):533-43.
39. Avedis Donabedian Rashid B. *An Introduction to Quality Assurance in Health Care: United States*: Oxford University Press; 2002.

40. Ameh S, Gómez-Olivé FX, Kahn K, Tollman SM, Klipstein-Grobusch K. Relationships between structure, process and outcome to assess quality of integrated chronic disease management in a rural South African setting: applying a structural equation model. *BMC Health Serv Res.* 2017;17.
41. Ayanian JZ, Markel H. Donabedian's Lasting Framework for Health Care Quality. *N Engl J Med.* 2016;375(3):205-7.
42. Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmaco-economic research. *Clin Ther.* 1993;15(6):1121-32; discussion 0.
43. Pollock M, Fernandes RM, Hartling L. Evaluation of AMSTAR to assess the methodological quality of systematic reviews in overviews of reviews of healthcare interventions. *BMC Med Res Methodol.* 2017;17(1):48.
44. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppert T, et al. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol.* 2012;73(5):691-705.
45. Taylor KMG, Harding G. *Pharmacy Practice.* Boca Raton: Boca Raton : CRC Press; 2001.
46. Eriksson T. Evidence-based and pragmatic steps for pharmacists to improve patient adherence 2015.
47. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ.* 2009;339:b2700.
48. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ.* 2017;358.
49. Aguiar PM, Brito GD, Correr CJ, Lyra Junior DP, Storpirtis S. Exploring the Quality of Systematic Reviews on Pharmacist Interventions in Patients With Diabetes: An Overview. *Ann Pharmacother.* 2014;48(7):887-96.
50. Melchior AC, Correr CJ, Venson R, Pontarolo R. An analysis of quality of systematic reviews on pharmacist health interventions. *Int J Clin Pharm.* 2012;34(1):32-42.
51. Shea BJR, B.C.; Wells, G.; Thuku, M.; Hamel, C.; Moran, J.; Moher, D.; Tugwell, P.; Welch, V.; Kristjansson, E.; Henry, D.A. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Ottawa: AMSTAR team; 2017 [Available from: <https://amstar.ca/docs/AMSTAR%202-Guidance-document.pdf>].
52. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol.* 2007;7:10.
53. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol.* 2009;62(10):1013-20.
54. Pollock M, Fernandes RM, Becker LA, Featherstone R, Hartling L. What guidance is available for researchers conducting overviews of reviews of healthcare interventions? A scoping review and qualitative metasummary. *Systematic Reviews.* 2016;5.
55. McCormack J, Vandermeer B, Allan GM. How confidence intervals become confusion intervals. *BMC Med Res Methodol.* 2013;13(1):134.
56. Al-ajeel S, Gershuni O, Al-sabhan J, Hilgsmann M. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. *Cochrane Database of Systematic Reviews.* 2017(2).
57. Dash D, Sebastian TM, Aggarwal M, Tripathi M. Impact of health education on drug adherence and self-care in people with epilepsy with low education. *Epilepsy Behav.* 2015;44:213-7.
58. Dilorio C, Bamps Y, Walker ER, Escoffery C. Results of a research study evaluating WebEase, an online epilepsy self-management program. *Epilepsy Behav.* 2011;22(3):469-74.

59. Mathes T, Antoine SL, Pieper D. Adherence-enhancing interventions for active antiretroviral therapy in sub-Saharan Africa: A systematic review and meta-analysis. *Sexual Health*. 2014;11(3):230-9.
60. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. *Lancet*. 2010;376(9755):1838-45.
61. Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lester RT, Mills EJ, Smieja M, et al. The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy. *PLoS One*. 2012;7(12):e46909.
62. Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S, et al. Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. *J Acquir Immune Defic Syndr*. 2008;48(5):611-9.
63. Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. *Eur Respir J*. 2018;51(1).
64. Bediang G, Stoll B, Elia N, Abena JL, Nolna D, Chastonay P, et al. SMS reminders to improve the tuberculosis cure rate in developing countries (TB-SMS Cameroon): a protocol of a randomised control study. *Trials*. 2014;15:35.
65. Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. *PLoS Med*. 2015;12(9):e1001876.
66. Mohammed S, Glennerster R, Khan AJ. Impact of a Daily SMS Medication Reminder System on Tuberculosis Treatment Outcomes: A Randomized Controlled Trial. *PLoS One*. 2016;11(11):e0162944.
67. Bond C. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. *Fam Pract*. 2007;24(2):189-200.
68. Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, Simoni JM, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. *PLoS Med*. 2011;8(3):e1000422.
69. Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. *J Acquir Immune Defic Syndr*. 2009;51(2):163-74.
70. Gould KA. A randomized controlled trial of a discharge nursing intervention to promote self-regulation of care for early discharge interventional cardiology patients. *Dimens Crit Care Nurs*. 2011;30(2):117-25.
71. Holland R, Brooksby I, Lenaghan E, Ashton K, Hay L, Smith R, et al. Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomised controlled trial. *BMJ*. 2007;334(7603):1098.
72. Levy ML, Robb M, Allen J, Doherty C, Bland JM, Winter RJ. A randomized controlled evaluation of specialist nurse education following accident and emergency department attendance for acute asthma. *Respir Med*. 2000;94(9):900-8.
73. Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. *Ann Intern Med*. 2007;146(10):714-25.
74. Nazareth I, Burton A, Shulman S, Smith P, Haines A, Timberal H. A pharmacy discharge plan for hospitalized elderly patients--a randomized controlled trial. *Age Ageing*. 2001;30(1):33-40.
75. Nieuwkerk PT, Nierman MC, Vissers MN, Locadia M, Greggers-Peusch P, Knape LP, et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. *Am J Cardiol*. 2012;110(5):666-72.

76. Pyne JM, Fortney JC, Curran GM, Tripathi S, Atkinson JH, Kilbourne AM, et al. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. *Arch Intern Med*. 2011;171(1):23-31.
77. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. *Br J Clin Pharmacol*. 2005;60(2):183-93.
78. Sherrard H, Struthers C, Kearns SA, Wells G, Chen L, Mesana T. Using technology to create a medication safety net for cardiac surgery patients: a nurse-led randomized control trial. *Can J Cardiovasc Nurs*. 2009;19(3):9-15.
79. Udelson JE, Pressler SJ, Sackner-Bernstein J, Massaro J, Ordroneau P, Lukas MA, et al. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. *J Card Fail*. 2009;15(5):385-93.
80. Vergouwen AC, Bakker A, Burger H, Verheij TJ, Koerselman F. A cluster randomized trial comparing two interventions to improve treatment of major depression in primary care. *Psychol Med*. 2005;35(1):25-33.
81. Wu JY, Leung WY, Chang S, Lee B, Zee B, Tong PC, et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. *BMJ*. 2006;333(7567):522.
82. Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. *Cochrane Database Syst Rev*. 2017;4:Cd012226.
83. Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP, et al. Effectiveness of pharmacist intervention for asthma control improvement. *Eur Respir J*. 2008;31(4):790-9.
84. NCT00414817. Telephone-based program to promote inhaled corticosteroid adherence among individuals with asthma [Phone calls to promote adherence with inhaled corticosteroids]. .
85. Vollmer WM, Feldstein A, Smith DH, Dubanoski JP, Waterbury A, Schneider JL, et al. Use of health information technology to improve medication adherence. *Am J Manag Care*. 2011;17(12 Spec No.):Sp79-87.
86. Vollmer WM, Xu M, Feldstein A, Smith D, Waterbury A, Rand C. Comparison of pharmacy-based measures of medication adherence. *BMC Health Serv Res*. 2012;12:155.
87. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. *BMC Pulm Med*. 2010;10:1.
88. Bruhn H, Bond CM, Elliott AM, Hannaford PC, Lee AJ, McNamee P, et al. Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial. *BMJ Open*. 2013;3(4).
89. Hunt JS, Siemieniczuk J, Pape G, Rozenfeld Y, MacKay J, LeBlanc BH, et al. A Randomized Controlled Trial of Team-Based Care: Impact of Physician-Pharmacist Collaboration on Uncontrolled Hypertension. *J Gen Intern Med*. 2008;23(12):1966-72.
90. Magid DJ, Olson KL, Billups SJ, Wagner NM, Lyons EE, Kroner BA. A pharmacist-led, American Heart Association Heart360 Web-enabled home blood pressure monitoring program. *Circ Cardiovasc Qual Outcomes*. 2013;6(2):157-63.
91. Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmaz HM, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. *JAMA*. 2013;310(1):46-56.
92. Zaugg V, Korb-Savoldelli V, Durieux P, Sabatier B. Providing physicians with feedback on medication adherence for people with chronic diseases taking long-term medication. *Cochrane Database of Systematic Reviews*. 2018(1).

93. Pladevall M, Divine G, Wells KE, Resnicow K, Williams LK. A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. *Diabetes Educ.* 2015;41(1):136-46.
94. Williams LK, Peterson EL, Wells K, Campbell J, Wang M, Chowdhry VK, et al. A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. *J Allergy Clin Immunol.* 2010;126(2):225-31, 31.e1-4.
95. Willis JM, Edwards R, Anstrom KJ, Johnson FS, Del Fiol G, Kawamoto K, et al. Decision support for evidence-based pharmacotherapy detects adherence problems but does not impact medication use. *Stud Health Technol Inform.* 2013;183:116-25.
96. Zhong H, Ni X-J, Cui M, Liu X-Y. Evaluation of pharmacist care for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Int J Clin Pharm.* 2014;36(6):1230-40.
97. Jarab AS, Alqudah SG, Khmour M, Shamssain M, Mukattash TL. Impact of pharmaceutical care on health outcomes in patients with COPD. *Int J Clin Pharm.* 2012;34(1):53-62.
98. Khmour MR, Kidney JC, Smyth BM, McElroy JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *Br J Clin Pharmacol.* 2009;68(4):588-98.
99. Khmour MR, Agus AM, Kidney JC, Smyth BM, McElroy JC, Crealey GE. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. *Int J Clin Pharm.* 2011;33(4):665-73.
100. Wei LL, J.; Luo, H.; Wei, Y.; Yang, X.; Liu, L. . Effects of pharmacy service on disease analysis and quality of life of chronic obstructive pulmonary disease. *China Med Herald.* 2013;10(17):163–5.
101. Wei LL, J.; Luo, H.; Wei, Y.; Yang, X.; Liu, L. . Effects of pharmaceutical care on drug compliance of patients with chronic obstructive pulmonary disease in stable phase. . *China Pharm.* 2013;24(14):1316–8.
102. Weinberger M, Murray MD, Marrero DG, Brewer N, Lykens M, Harris LE, et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. *JAMA.* 2002;288(13):1594-602.
103. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. *Eur J Epidemiol.* 2016;31(4):337-50.
104. Stang A, Poole C, Kuss O. The ongoing tyranny of statistical significance testing in biomedical research. *Eur J Epidemiol.* 2010;25(4):225-30.
105. Rothman KJ. Curbing type I and type II errors. *Eur J Epidemiol.* 2010;25(4):223-4.
106. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev.* 2014(4):Cd007768.
107. Conn VS, Ruppert TM. Medication adherence outcomes of 771 intervention trials: Systematic review and meta-analysis. *Prev Med.* 2017;99(Supplement C):269-76.
108. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care.* 1986;24(1):67-74.
109. Bondesson A, Hellstrom L, Eriksson T, Hoglund P. A structured questionnaire to assess patient compliance and beliefs about medicines taking into account the ordered categorical structure of data. *J Eval Clin Pract.* 2009;15(4):713-23.
110. Apotekerforeningen. Farmasøytrevirering. Apotekerforeningens tidsskrift. 2011;3:6-19.
111. van Dulmen S, van Bijnen E. What makes them (not) talk about proper medication use with their patients? An analysis of the determinants of GP communication using reflective practice. 2011. 2011;1(1):8.
112. Lavis JN, Posada FB, Haines A, Osei E. Use of research to inform public policymaking. *Lancet.* 2004;364(9445):1615-21.
113. Urquhart J. Defining the margins for errors in patient compliance with prescribed drug regimens. *Pharmacoepidemiol Drug Saf.* 2000;9(7):565-8.

114. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. *J Clin Epidemiol.*54(12):S57-S60.
115. Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. *Quality & safety in health care.* 2003;12(4):280-5.
116. Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. *Cochrane Database of Systematic Reviews.* 2017;2017 (4) (no pagination)(CD012226).
117. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. *Med Care.* 2005;43(6):521-30.
118. Sitzia J, Wood N. Patient satisfaction: a review of issues and concepts. *Soc Sci Med.* 1997;45(12):1829-43.
119. Testa MA, Nackley JF. Methods for quality-of-life studies. *Annu Rev Public Health.* 1994;15:535-59.